Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal drug-loaded vesicles after radical hepatobiliary cancer resection
ChiCTR2300078719Phase 4Not yet recruiting
- Sponsor
- Tianjin Third Central Hospital
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of AQ001S in hepatobiliary cancer (HBC), hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) (2 arms), sponsored by Tianjin Third Central Hospital. Primary endpoint: Immune cell subsets. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
AQ001S
03
Conditions
hepatobiliary cancer (HBC)hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2300078719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078719.